Tumor News and Research

RSS

Excess EXO1 protein may drive cancer DNA damage and treatment response

When it comes to cancer, tumor suppressor genes are usually thought of as the "good guys." These genes make proteins that protect and repair DNA in cells.

21 May 2026

Experimental virus therapy targets resistant high-grade neuroendocrine tumors

A phase I clinical trial is testing whether a tumor-targeting virus can help immunotherapy work more effectively against aggressive neuroendocrine tumors that often resist treatment.

21 May 2026

Artificial intelligence-based tool could improve multiple myeloma treatment decisions

An artificial intelligence-based tool may help physicians determine which newly diagnosed multiple myeloma patients are most likely to benefit from specific therapies, including immunotherapy and stem cell transplantation.

21 May 2026

Specific gene fusion patterns tied to solitary fibrous tumor outcomes

Specific genetic fusion patterns in solitary fibrous tumors may help identify which patients face a higher risk of metastasis, recurrence and more aggressive disease behavior, according to new research that could improve how physicians assess and eventually treat this rare cancer.

21 May 2026

Vitamin B12 analog targets deadly brain cancer cells

A new research paper was published in Volume 13 of Oncoscience on April 2, 2026, titled "Selective blood–brain barrier penetration and tumor targeting of nitrosylcobalamin in glioblastoma: Pharmacokinetics, tissue distribution, and synergistic activity with trail and temozolomide."

21 May 2026

Researchers discover unexpected cellular triggers for precancerous pancreas lesions

In an unexpected finding, a new study flips on its head researchers' understanding of how precancerous pancreas lesions evolve into pancreatic cancer.

21 May 2026

Targeting tumor-specific inflammatory process may prevent drug resistance in colon cancer

Chemotherapy drugs that target a common mutation in colorectal cancer rapidly lose efficacy in patients, leading to relapse.

21 May 2026

New gene expression signature may guide immunotherapy for resistant prostate cancer patients

Researchers with the James P. Allison Institute™ at The University of Texas MD Anderson Cancer Center have discovered a new gene expression signature within tumors that can help identify patients with metastatic castration-resistant prostate cancer (mCRPC) who are more likely to experience lasting benefits from combined immunotherapy treatment.

21 May 2026

New CA19-9 threshold improves pancreatic cancer risk prediction accuracy

A dual-threshold model for measuring the pancreatic tumor marker serum carbohydrate antigen 19-9 (CA19-9) identified patients with pancreatic cancer who had high-risk disease despite having low CA19-9 levels because of a genetic variation that impairs their ability to produce this biomarker.

21 May 2026

Small T-cell subset drives powerful multiple myeloma immunotherapy responses

Researchers from The University of Osaka find that only a small fraction of T cells may drive the robust anti-cancer response seen in breakthrough multiple myeloma immunotherapy.

21 May 2026

Bioluminescent fungi reveal pathways for advanced biotechnology and medical applications

Like fireflies and many deep-sea creatures, certain fungi can naturally emit light through bioluminescence pathways in which specialized enzymes convert chemical energy into visible light.

21 May 2026

Light-driven nanomotors improve multimodal breast cancer treatment efficacy

The nanomotor starts with bowl‑shaped mesoporous polydopamine (PDA) nanoparticles. These biocompatible bowls are loaded with two key payloads: Fe(II) ions as a Fenton catalyst, and BNN6, a thermally sensitive NO donor.

21 May 2026

Polymer-based immunotherapies enhance tumor targeting and immune activation

Conventional immune checkpoint inhibitors, such as anti-PD-1/PD-L1 and anti-CTLA-4 antibodies, can reinvigorate T cells but typically benefit less than 30% of patients.

21 May 2026

Cytokine-armored CAR-T cell therapy successfully attacks aggressive brain tumors in mice

Scientists at the UCLA Health Jonsson Comprehensive Cancer Center have developed a new cytokine-armored CAR-T cell therapy that helps the immune system better attack aggressive brain tumors in mice while reducing dangerous side effects that have long limited immune-based treatments for glioblastoma, one of the deadliest and most treatment-resistant brain cancers.

20 May 2026

Restoring ADAR2 enzyme reduces metastatic spread in osteosarcoma

Osteosarcoma is the most common primary bone cancer in children, adolescents, and young adults. Although chemotherapy and surgery have improved survival for localized disease, outcomes remain poor when tumors spread to the lungs or return after treatment.

20 May 2026

Tumor microenvironment markers forecast immunotherapy response in rare cancers

A new study in Cell Reports Medicine from researchers at The University of Texas MD Anderson Cancer Center identified key features that may help predict which types of rare cancers are likely to respond to immunotherapy.

20 May 2026

Fluid viscosity drives mechanical memory and invasion in glioblastoma

Most cancer studies focus on chemical signals or stiff tumor surroundings, but the stickiness of the fluid itself has received little attention.

20 May 2026

Engineered nanomaterials optimize delivery barriers in cancer immunotherapy

Cancer immunotherapy works by mobilizing the body's own immune system to recognize and destroy malignant cells.

20 May 2026

Spatial modeling of tissue compartments predicts breast cancer treatment response

HER2-positive breast cancer accounts for about 20% of breast cancer cases and is generally associated with more aggressive behavior and a higher risk of distant metastasis, while pathologic complete response (pCR) after neoadjuvant chemotherapy is strongly linked to better survival outcomes.

20 May 2026

Scientists uncover why genome guardian p53 protein is uniquely prone to collapse

The protein p53 is often called the guardian of the genome for its central role in preventing cancer. Yet paradoxically, it is also one of the most frequently mutated and dysfunctional proteins in human tumors.

20 May 2026

Previous
1
...
23
24
25
26
27
28
29
...
1367
Next

Tumor News and Research

Excess EXO1 protein may drive cancer DNA damage and treatment response

Experimental virus therapy targets resistant high-grade neuroendocrine tumors

Artificial intelligence-based tool could improve multiple myeloma treatment decisions

Specific gene fusion patterns tied to solitary fibrous tumor outcomes

Vitamin B12 analog targets deadly brain cancer cells

Researchers discover unexpected cellular triggers for precancerous pancreas lesions

Targeting tumor-specific inflammatory process may prevent drug resistance in colon cancer

New gene expression signature may guide immunotherapy for resistant prostate cancer patients

New CA19-9 threshold improves pancreatic cancer risk prediction accuracy

Small T-cell subset drives powerful multiple myeloma immunotherapy responses

Bioluminescent fungi reveal pathways for advanced biotechnology and medical applications

Light-driven nanomotors improve multimodal breast cancer treatment efficacy

Polymer-based immunotherapies enhance tumor targeting and immune activation

Cytokine-armored CAR-T cell therapy successfully attacks aggressive brain tumors in mice

Restoring ADAR2 enzyme reduces metastatic spread in osteosarcoma

Tumor microenvironment markers forecast immunotherapy response in rare cancers

Fluid viscosity drives mechanical memory and invasion in glioblastoma

Engineered nanomaterials optimize delivery barriers in cancer immunotherapy

Spatial modeling of tissue compartments predicts breast cancer treatment response

Scientists uncover why genome guardian p53 protein is uniquely prone to collapse

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News